Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plastoquinonyl decyl triphenylphosphonium - Mitotech

Drug Profile

Plastoquinonyl decyl triphenylphosphonium - Mitotech

Alternative Names: Plastomitin; SkQ-1; SkQ1 eye drops; SkQ1 pill; Visomitin

Latest Information Update: 28 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitotech
  • Class Anti-inflammatories; Benzoquinones; Eye disorder therapies; Halogenated hydrocarbons; Organophosphorus compounds; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leber's hereditary optic atrophy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry eyes
  • Phase II Leber's hereditary optic atrophy
  • Phase I Dry age-related macular degeneration; Glaucoma
  • No development reported Acute kidney injury; Barth syndrome; Inflammation; Multiple sclerosis; Neurodegenerative disorders; Uveitis; Wet age-related macular degeneration

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for preclinical development in Acute kidney injury in USA (PO, Pill)
  • 28 Jan 2022 No recent reports of development identified for phase-I development in Dry age-related macular degeneration in USA (Ophthalmic, Drops)
  • 28 Jan 2022 No recent reports of development identified for phase-I development in Uveitis in USA (Ophthalmic, Drops)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top